Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1CNS 1

Conditions

Lymphoma 447Precursor Cell Lymphoblastic Leukemia-Lymphoma 413Lymphoma, Large B-Cell, Diffuse 348Lymphoma, Non-Hodgkin 317Leukemia, Lymphocytic, Chronic, B-Cell 286Leukemia 260Lymphoma, Follicular 241Burkitt Lymphoma 217Lymphoma, Mantle-Cell 202Hodgkin Disease 193Leukemia, Myeloid, Acute 190Myelodysplastic Syndromes 172Lymphoma, B-Cell, Marginal Zone 142Multiple Myeloma 116Lymphoma, Large-Cell, Immunoblastic 116Lymphoma, B-Cell 103Recurrence 100Leukemia, Myelogenous, Chronic, BCR-ABL Positive 76Myeloproliferative Disorders 75Leukemia, Myeloid, Chronic-Phase 73Dendritic Cell Sarcoma, Interdigitating 73Leukemia, Myeloid, Accelerated Phase 72Leukemia, Myelomonocytic, Chronic 67Lymphoma, Large-Cell, Anaplastic 65Waldenstrom Macroglobulinemia 63Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 63Neoplasms, Plasma Cell 59Blast Crisis 58Primary Myelofibrosis 54Congenital Abnormalities 52

Interventions

siltuximab 2fludarabine phosphate 2fludarabine 2Interleukin 1 Receptor Antagonist Protein 2Cyclophosphamide 2AP 1903 reagent 2obinutuzumab 1glofitamab 1axicabtagene ciloleucel 1Oxaliplatin 1Neuropsychological Tests 1Magnetic Resonance Spectroscopy 1Gemcitabine 1Gelsolin 1Contrast Media 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × Cyclophosphamide × Lymphoid × Clear all
NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 1 Active not recruiting
19 enrolled
Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡